Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Chemomab is developing CM-101, a blocking mAb that targets CCL24, which is a chemokine that modulates inflammatory and fibrotic processes through its receptor CCR3
Although these agents produce substantial and sustained weight reduction, emerging clinical observations suggest that chronic therapy may be accompanied by changes in lean mass trajectory, reduced protein intake, and micronutrient insufficiency
Kwegyir-Afful, A
This sudden change can make it difficult to stick to previous portion sizes or dietary habits
US$ 25.15
US$ 25.72
US$ 23.79
US$ 27.74
US$ 27.47
